Jonathan D. Alspaugh M.B.A. Net Worth

The estimated Net Worth of Jonathan Alspaugh is at least $1.99 Milion dollars as of 11 March 2022. Mr Alspaugh owns over 75,000 units of Aeglea BioTherapeutics Inc stock worth over $1,986,118 and over the last 3 years he sold AGLE stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr A AGLE stock SEC Form 4 insiders trading

Mr has made over 3 trades of the Aeglea BioTherapeutics Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he bought 75,000 units of AGLE stock worth $156,000 on 11 March 2022.

The largest trade he's ever made was buying 75,000 units of Aeglea BioTherapeutics Inc stock on 11 March 2022 worth over $156,000. On average, Mr trades about 20,672 units every 26 days since 2021. As of 11 March 2022 he still owns at least 165,372 units of Aeglea BioTherapeutics Inc stock.

You can see the complete history of Mr Alspaugh stock trades at the bottom of the page.

Mr. Jonathan D. Alspaugh M.B.A. biography

Jonathan D. Alspaugh M.B.A. is the Chief Financial Officer at Aeglea BioTherapeutics Inc.

What's Mr A's mailing address?

Jonathan's mailing address filed with the SEC is C/O AEGLEA BIOTHERAPEUTICS, INC., 805 LAS CIMAS PARKWAY, SUITE 100, AUSTIN, TX, 78746.

Insiders trading at Aeglea BioTherapeutics Inc

Over the last 8 years, insiders at Aeglea BioTherapeutics Inc have traded over $1,425,674 worth of Aeglea BioTherapeutics Inc stock and bought 1,931,829 units worth $12,152,489 . The most active insiders traders include Bros. Advisors Lp667, L.P.B..., Bioventures Ltd Novartis Ag... a Advisors Llc Orbi Med Capit.... On average, Aeglea BioTherapeutics Inc executives and independent directors trade stock every 70 days with the average trade being worth of $864,564. The most recent stock trade was executed by Marcio Souza on 25 August 2022, trading 90,000 units of AGLE stock currently worth $50,400.

What does Aeglea BioTherapeutics Inc do?

aeglea was founded in december of 2013 to develop engineered human enzymes invented in the laboratory of george georgiou, ph.d. of the university of texas at austin. the convergence of discovery and technology has created a significant opportunity for aeglea to impact both the treatment of inborn errors of metabolism and cancer. three drug candidates that degrade specific amino acids in the circulation are in development. for inborn errors of metabolism efforts are underway to normalize high arginine levels in patients who suffer from a gene mutation in the arginine degrading enzyme arginase1 and for patients who have mutations leading to excess levels of homocysteine. taking advantage of a cancer’s metabolic vulnerability and selectively killing only the tumor through deprivation of arginine, cysteine/cystine, and methionine are techniques in development for multiple oncology indications. coupling amino acid depletion therapy with the development of diagnostics for each oncology f

Complete history of Mr Alspaugh stock trades at Aeglea BioTherapeutics Inc

Aeglea BioTherapeutics Inc executives and stock owners

Aeglea BioTherapeutics Inc executives and other stock owners filed with the SEC include:

• Anthony Quinn,
  President and Chief Executive Officer, Director
• Leslie Sloan,
  Chief Operating Officer
• Charles York,
  Chief Financial Officer, Vice President
• Dr. Anthony G. Quinn M.D., M.B Ch.B., Ph.D., FRCP,
  Pres, CEO & Director
• Dr. Leslie S. Sloan Ph.D.,
  Chief Operating Officer
• Russell Cox,
  Independent Chairman of the board
• Sandesh Mahatme,
  Independent Director
• Suzanne Bruhn,
  Independent Director
• Ivana Magovcevic-Liebisch,
  Independent Director
• V. Bryan Lawlis,
  Independent Director
• Armen Shanafelt,
  Independent Director
• Joey Perrone,
  Director, Finance & Investor Relations
• Ravi Rao,
  Chief Medical Officer
• Michael Hanley,
  Chief Commercial Officer
• Michael C. Hanley M.B.A.,
  Chief Commercial Officer
• Eugene Sackett,
  VP of HR
• Kelly Boothe Ph.D.,
  Sr. Director of Corp. Communications
• James Paul Kastenmayer J.D., Ph.D.,
  Gen. Counsel
• Cortney Caudill M.B.A.,
  Sr. VP of Technical Operations
• Steven Weber,
  VP, Principal Accounting Officer & Corp. Controller
• Jonathan D. Alspaugh M.B.A.,
  Chief Financial Officer
• Aaron Schuchart,
  Chief Business Officer
• Joseph E Tyler,
  VP, Manufacturing
• Scott W Rowlinson,
  VP, Research
• David George Lowe,
  CEO and President
• Henry Hebel,
  VP, Product Development
• Advisors Llc Orbi Med Capit...,
  
• George Georgiou,
  Director
• Lilly & Co Eli,
  10% owner
• Bioventures Ltd Novartis Ag...,
  
• Laurie Stelzer,
  
• Jeffrey W. Albers,
  
• Cameron Turtle,
  Chief Executive Officer
• Funds Management Llc Fairmo...,
  
• Heidy King Jones,
  See Remarks
• Scott L Burrows,
  Chief Financial Officer
• James Wooldridge,
  Chief Medical Officer
• Linda L Neuman,
  Chief Medical Officer
• Alison Frances Lawton,
  Director
• Marcio Souza,
  Director
• Steven Weber,
  VP, Controller&Princ Acctg Off
• Bros. Advisors Lp667, L.P.B...,
  
• Hunter C Smith,
  Director
• James Paul Kastenmayer,
  General Counsel
• Jeff Marc Goldberg,
  President and CEO
• Jonathan Alspaugh,
  President and CFO